The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes. A 26-week, randomised, open-label, parallel-group, multicentre, multinational trial with a 26-week extension - ND
- Conditions
- Type 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus
- Registration Number
- EUCTR2007-005317-19-IT
- Lead Sponsor
- OVO NORDISK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 940
1. Informed consent obtained before any trial-related activities (trial-related activities are any procedure that would not have been performed during normal management of the subject) 2. Subjects diagnosed with type 2 diabetes, insulin naïve and treated with metformin as monotherapy for  3 months prior to screening, at a stable dose of  1500 mg/day or metformin ( 1500 mg/day) and a sulfonylurea (less than or equal to œ of the maximum approved dose according to local label), both at a stable dose for  3 months prior to screening. Previous short-term insulin treatment in connection with intercurrent illness is allowed, at the discretion of the Investigator. 3. HbA1c 7.0-10.0% (both inclusive) for subjects on metformin monotherapy HbA1c 7.0-8.5% (both inclusive) for subjects on metformin in combination with a sulfonylurea 4. Age 18-80 years, both inclusive (or as allowed according to local guidelines) 5. Able and willing to perform self-monitoring of plasma glucose according to the protocol, to keep a diabetes diary and willing to use pen-injector device and FlexPen device if necessary.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1. Previous treatment with insulin (except for short-term treatment in connection with intercurrent illness at the discretion of the Investigator) 2. Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 3 months prior to screening 3. Impaired liver function, defined as alanine aminotransferase (ALAT)  2.5 times upper normal limit (one retest analysed at the central laboratory within a week is permitted with the result of the last sample being the conclusive) 4. Impaired renal function defined as serum-creatinine  133 µmol/L ( 1.5 mg/dL) for males and  115 µmol/L ( 1.4 mg/dL) for females, or as allowed according to local contraindications for metformin or sulfonylurea use (one retest analysed at the central laboratory within a week permitted with the result of the last sample being the conclusive) 5. History of chronic pancreatitis or idiopathic acute pancreatitis 6. Known history of unstable angina, acute coronary event, other significant cardiac event (including history of arrhythmias or conduction delays on ECG), or cerebral stroke within the past 6 months. 7. Heart failure NYHA class IV (see appendix D) 8. Known proliferative retinopathy or maculopathy requiring acute treatment as judged by the Investigator 9. Uncontrolled treated or untreated hypertension (systolic blood pressure  180 mmHg and/or diastolic blood pressure  110 mmHg) 10. Cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically significant disorder, except for conditions associated with type 2 diabetes history which in the Investigator?s opinion could interfere with the results of the trial 11. Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator 12. Known or suspected allergy to trial product(s) or related products 13. Use of any drug (except for those stated in the inclusion criteria), which in the Investigator?s opinion could interfere with the glucose level (eg systemic corticosteroids) 14. Receipt of any other investigational drug within 3 months prior to screening into this trial 15. Any contraindications to metformin or insulin detemir according to the local label 16. Surgery scheduled for the trial duration period (excluding minor surgical procedures performed in local anaesthesia, as judged by the Investigator) 17. Previous participation in the run-in period of this trial. 18. Known or suspected abuse of alcohol or narcotics 19. Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) UK: Adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, sterilisation, intrauterine device or intrauterine system, or consistent use of barrier methods. France: Adequate contraceptive measures are defined as oral hormonal method of contraception or intrauterine device. Germany: Adequate contraceptive measures are implants, injectables, combined oral contraceptives, hormonal IUD, sexual abstinence or vasectomised partner. 20. Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method